1. Introduction {#sec1}
===============

Ankylosing spondylitis (AS) represents a chronic inflammatory arthritis, which affects the axial joints such as spine and sacroiliac joints \[[@B1]\]. It causes serious spinal mobility impairment and influences the quality of life \[[@B2]\]. Ankylosing spondylitis is a complex and systemic rheumatic disease; hence systematic screening is required to improve the diagnosis and treatment of ankylosing spondylitis.

Rapid growth of high-throughput transcriptomic data largely enables gene expression profiling and diagnostic targets identification in disease nowadays. In the past decade, several studies have focused on the transcriptional profiling of ankylosing spondylitis using microarrays to identify candidate genes involved in ankylosing spondylitis \[[@B3], [@B4]\]. Analysis of multiple transcriptomic datasets has the likelihood of discovering robust candidates for diagnosis and treatment. Therefore, we investigated gene expression patterns between ankylosing spondylitis patients and healthy controls in a meta-analysis based on public microarray datasets. The differently expressed genes identified in the meta-analysis were further interpreted by gene ontology analysis and pathway analysis.

To carry out these studies, we used the INMEX (integrative meta-analysis of expression data) program \[[@B5]\]. Careful data procession and annotation were done to insure that the data format and class labels were consistent across datasets. Due to the differences in study design and platform usage, heterogeneity exists among microarray datasets. To address this, we applied the combing rank orders algorithm based on the RankProd package \[[@B6]\], which is robust facing outliers and variations among studies, to carry out the meta-analysis.

2. Materials and Methods {#sec2}
========================

2.1. Microarray Datasets Search and Selection {#sec2.1}
---------------------------------------------

In this study, we searched public microarray study till March 18, 2014, according to the keywords "ankylosing spondylitis" in Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) \[[@B7]\]. The studies obtained were further selected for the meta-analysis and our selection criteria were (a) case-control study; (b) study providing gene expression data; and (c) study with ankylosing spondylitis patients diagnosed based on the modified New York criteria \[[@B8]\]. Animal studies and studies not about ankylosing spondylitis were excluded in this meta-analysis.

Two investigators independently collected data from each eligible study. The data were composed of GEO accession, sample size, sample source, platform, and gene expression data. Through checking between the two investigators, a final data collection was determined.

2.2. Meta-Analysis Methods {#sec2.2}
--------------------------

According to the data collected from each eligible microarray study, we performed an overall meta-analysis to identify differentially expressed (DE) genes in ankylosing spondylitis. In this study, we used the INMEX (integrative meta-analysis of expression data) program (<http://www.inmex.ca/INMEX/>) \[[@B5]\] to carry out the meta-analysis.

All eligible datasets were uploaded to INMEX, then processed, and annotated to insure that the data format and class labels were consistent across datasets. After data integrity check, we carried out a meta-analysis using combing rank orders algorithm, with 100 times of permutation tests. The combing rank order algorithm is based on the RankProd package \[[@B6]\] and is robust facing outliers and variations among studies.

2.3. Functional Interpretation Methods {#sec2.3}
--------------------------------------

Functional interpretation (gene ontology analysis and pathway analysis) of the DE genes identified in the meta-analysis was further performed using the INMEX program. In gene ontology (GO) analysis, a *P* value threshold of 0.05 was used to identify significantly enriched GO terms \[[@B9]\]. In pathway analysis, enrichment analysis was carried out using the hypergeometric test with a *P* value threshold of 0.05 based on the KEGG database \[[@B10]\].

3. Results {#sec3}
==========

3.1. Studies and Data Included in This Meta-Analysis {#sec3.1}
----------------------------------------------------

Original search identified 8 studies in total. Then, 5 studies were excluded among which 4 were not about the DE genes between ankylosing spondylitis patients and healthy controls, and 1 was animal study. Through searching and selection, a final list of 3 microarray datasets \[[@B3], [@B4]\] was collected for meta-analysis. In total, the 3 eligible datasets consisted of 26 cases and 29 controls. All 3 datasets provided case-control data with various sample sources (1 dataset of synovial biopsies sample and 2 datasets of blood sample). The detailed information of these 3 datasets is presented in [Table 1](#tab1){ref-type="table"}. Heat map of rescaled individual expression data for a subset of genes across the 3 datasets is shown in [Figure 1](#fig1){ref-type="fig"}, and the patterns of change for a gene among different datasets could be visualized.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

In this study we performed the meta-analysis based on combing rank orders, and the DE genes with *P* value \< 0.05 were selected. Overall, there were 743 gained genes and 167 lost genes in this meta-analysis ([Figure 2](#fig2){ref-type="fig"}, see Supplementary Table 1 in Supplementary Materials available online at <http://dx.doi.org/10.1155/2014/826316>). Gain genes are those identified to be differentially expressed uniquely in the meta-analysis. The expression profiles of gain genes are relatively weak but consistent across datasets. They benefit by larger sample size and hence are more reliable DE genes. Lost genes are those identified to be differentially expressed in individual analysis rather than in the meta-analysis. The expression profiles of lost genes vary largely across different datasets \[[@B5]\].

In total, according to the results of our meta-analysis, 905 genes were identified to be differentially expressed between ankylosing spondylitis patients and healthy controls across microarray datasets (Supplementary Table 2). Among the 905 DE genes, 482 genes were upregulated and 423 genes were downregulated. The top 10 most significantly upregulated genes and top 10 most significantly downregulated genes are shown in [Table 2](#tab2){ref-type="table"}. The upregulated gene with the smallest combined rank product (RP) was*GNG11* (combined RP = 299.64). GNG11, guanine nucleotide binding protein (G protein) gamma 11, is a member of the G protein gamma family which functions in the transmembrane signaling system and cellular senescence \[[@B11], [@B12]\]. The downregulated gene with the smallest combined RP was*S100P* (combined RP = 335.94). S100P (S100 calcium binding protein P) belongs to the S100 calcium-binding protein family and functions in the regulation of diverse cellular processes \[[@B13]\]. However, neither*GNG11* nor*S100P* have been reported to be associated with ankylosing spondylitis yet.

Many consistently DE genes across datasets identified are involved in immune regulation, such as*COMMD6*,*C19orf59*,*CCR7*,*CX3CR1*,*CFD*, and*FGFBP2* (see [Table 2](#tab2){ref-type="table"}). Although these results are suggestive rather than straightforward, those DE genes could be involved in the pathogenesis of ankylosing spondylitis and further research is required.

3.3. Advanced Analyses Results {#sec3.3}
------------------------------

Advanced analyses (GO analysis and pathway analysis) were carried out for further functional investigation of the DE genes. [Figure 3](#fig3){ref-type="fig"} presented a summary of the GO analysis results. In the GO analysis, 715 GO terms were significantly enriched for the DE genes (see Supplementary Table 3), and the three most significantly enriched GO terms were "immune system process" (*P* = 3.46 × 10^−26^), "immune response" (*P* = 7.83 × 10^−24^), and "defense response" (*P* = 6.99 × 10^−16^) ([Table 3](#tab3){ref-type="table"}). In the pathway analysis, 15 significant pathways were identified when we mapped the DE genes to the KEGG database (see supplementary Table 4), and the three most significant pathways were antigen processing and presentation (*P* = 8.40 × 10^−5^), measles (*P* = 3.30 × 10^−3^), and cell adhesion molecules (CAMs) (*P* = 5.66 × 10^−3^) ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

A number of genes have been reported to be upregulated or downregulated in ankylosing spondylitis patients \[[@B14]--[@B16]\]. Identification of the most important candidate genes and pathways involved in ankylosing spondylitis pathogenesis is a challenge currently. Growing high-throughput transcriptomic data enables meta-analysis of multiple datasets which has the likelihood of discovering robust candidates for diagnosis and treatment. Hence in this study, we performed a meta-analysis of multiple public microarray datasets to identify potential transcriptomic markers in developing ankylosing spondylitis.

In the meta-analysis, 905 consistently DE genes were identified in ankylosing spondylitis, among which 482 genes were upregulated and 423 genes were downregulated. The upregulated gene with the smallest combined RP was*GNG11*. GNG11 belongs to the G protein gamma family and plays a role in the transmembrane signaling system and cellular senescence \[[@B11], [@B12]\]. The downregulated gene with the smallest combined RP was*S100P*.*S100P* encodes a protein which is a member of the S100 calcium-binding protein family and functions in the regulation of diverse cellular processes \[[@B13]\]. So far,*S100P* is reported to be involved in the development and progression of various cancers \[[@B13]\]. Although the exact contributions of these DE genes to ankylosing spondylitis development are not clear yet, further research is necessary as those genes could be potential transcriptomic markers for ankylosing spondylitis.

Many consistently DE genes identified are involved in immune regulation, suggesting its major role in ankylosing spondylitis development. A set of DE genes without previous studies in ankylosing spondylitis were also identified in our analysis. Some of these DE genes may function in the pathogenesis of ankylosing spondylitis and could be potential biomarkers.

In the GO analysis, 715 significantly enriched GO terms were identified in total. The top three significantly enriched GO terms were "immune system process," "immune response," and "defense response." Similar features were also shown in a previous microarray analysis of ankylosing spondylitis mouse model \[[@B17]\]. The overlap of enriched GO terms between human study and mouse study suggests that immune response plays a major role in ankylosing spondylitis development and therefore deserves further studies. In the pathway analysis, 15 significant pathways were identified in all. The top three significant pathways were antigen processing and presentation, measles, and cell adhesion molecules (CAMs). Our result that pathways involved in immune response are related with the pathogenesis of ankylosing spondylitis is consistent with previous reports highlighting innate immune stimulation and the IL-23 pathway in ankylosing spondylitis pathogenesis \[[@B18], [@B19]\]. Our analysis also identified pathways not previously studied in ankylosing spondylitis, some of which may harbor interesting functions and deserve further investigation.

In addition, all the results of our meta-analysis should be considered prudently due to the existence of several limitations. One limitation is the insufficient sample size used in our meta-analysis. A second limitation is the lack of subgroup analyses based on potential influential factors, including age, sex, treatment, disease severity, and platform usage, as ankylosing spondylitis is reported to be more prevalent in men and often occur in the third decade of life \[[@B1]\]. The third limitation is that biological knowledge base and pathway information are far from being complete at present and need further investigation. Hence, in order to achieve a more convincible conclusion, further analysis using larger sample size and more complete biological knowledge base and pathway information is required, and stratified analyses on different factors such as age, sex, disease severity, and platform usage are needed. In addition, experimental verification of the candidate DE genes identified should also be performed in the future, and functional studies need to be carried out as well to address the exact roles of those candidate DE genes in ankylosing spondylitis.

In conclusion, we identified consistently DE genes in ankylosing spondylitis that could potentially serve as transcriptomic markers. GO and pathway analyses revealed that those candidates strongly were associated with immune system process besides the underlying complex and multifactor-influenced molecular mechanism. These results provide novel insights into the pathogenesis of ankylosing spondylitis and promote the generation of diagnostic gene sets.
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Supplementary Table 1: The 743 gained genes and 167 lost genes in this meta-analysis.
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###### 

Studies and data included in this meta-analysis.

  Study   GEO accession   Sample size   Sample source   Platform            
  ------- --------------- ------------- --------------- ------------------- ------------------------------------------------------
  1       GSE41038        2             4               Synovial biopsies   GPL6883 Illumina HumanRef-8 v3.0 expression beadchip
  2       GSE25101        16            16              Blood               GPL6947 Illumina HumanHT-12 V3.0 expression beadchip
  3       GSE11886        8             9               Blood               GPL570 Affymetrix Human Genome U133 Plus 2.0 Array

GEO: Gene Expression Omnibus; AS: ankylosing spondylitis.

###### 

The 10 most significantly upregulated and 10 most significantly downregulated genes in ankylosing spondylitis.

  Entrez ID                                   Gene symbol   Gene full name                                                    Combined rank product   Average log fold change
  ------------------------------------------- ------------- ----------------------------------------------------------------- ----------------------- -------------------------
  10 most significantly upregulated genes                                                                                                             
  2791                                        *GNG11*       Guanine nucleotide binding protein (G protein), gamma 11          299.64                  0.380467
  51372                                       *TMA7*        Translation machinery associated 7 homolog (*S. cerevisiae*)      312.39                  0.610581
  9349                                        *RPL23*       Ribosomal protein L23                                             324.13                  0.148532
  23643                                       *LY96*        Lymphocyte antigen 96                                             330.33                  0.195432
  170622                                      *COMMD6*      COMM domain containing 6                                          332.47                  0.293187
  5909                                        *RAP1GAP*     RAP1 GTPase activating protein                                    343.66                  0.223733
  1349                                        *COX7B*       Cytochrome c oxidase subunit VIIb                                 371.12                  0.132367
  6283                                        *S100A12*     S100 calcium binding protein A12                                  439.12                  0.334567
  27258                                       *LSM3*        LSM3 homolog, U6 small nuclear RNA associated (*S. cerevisiae*)   440.15                  0.596028
  199675                                      *C19orf59*    Chromosome 19 open reading frame 59                               494.30                  0.358146
                                                                                                                                                      
  10 most significantly downregulated genes                                                                                                           
  6286                                        *S100P*       S100 calcium binding protein P                                    335.94                  −0.199948
  3560                                        *IL2RB*       Interleukin 2 receptor, beta                                      351.04                  −0.166370
  221178                                      *SPATA13*     Spermatogenesis associated 13                                     473.13                  −0.442046
  9289                                        *GPR56*       G protein-coupled receptor 56                                     528.50                  −0.239562
  22848                                       *AAK1*        AP2 associated kinase 1                                           530.65                  −0.364595
  5551                                        *PRF1*        Perforin 1 (pore forming protein)                                 531.02                  −0.114758
  1236                                        *CCR7*        Chemokine (C-C motif) receptor 7                                  609.87                  −0.199449
  1524                                        *CX3CR1*      Chemokine (C-X3-C motif) receptor 1                               622.12                  −0.351950
  1675                                        *CFD*         Complement factor D (adipsin)                                     636.15                  −0.365854
  83888                                       *FGFBP2*      Fibroblast growth factor binding protein 2                        653.39                  −1.054696

###### 

The 10 most significantly enriched GO terms for the DE genes in ankylosing spondylitis.

  ID           Term                                  *P* value
  ------------ ------------------------------------- --------------
  GO:0002376   Immune system process                 3.46*E* − 26
  GO:0006955   Immune response                       7.83*E* − 24
  GO:0006952   Defense response                      6.99*E* − 16
  GO:0002682   Regulation of immune system process   3.01*E* − 13
  GO:0006950   Response to stress                    2.02*E* − 12
  GO:0050776   Regulation of immune response         1.44*E* − 11
  GO:0001775   Cell activation                       2.24*E* − 11
  GO:0045087   Innate immune response                5.19*E* − 11
  GO:0045321   Leukocyte activation                  1.32*E* − 10
  GO:0030097   Hemopoiesis                           2.91*E* − 10

###### 

The 10 most significant pathways identified when the DE genes were mapped to the KEGG database.

  Pathway                                     *P* value
  ------------------------------------------- -----------
  Antigen processing and presentation         0.0000840
  Measles                                     0.0032959
  Cell adhesion molecules (CAMs)              0.0056626
  Jak-STAT signaling pathway                  0.0070316
  Hypertrophic cardiomyopathy (HCM)           0.0099861
  Pathogenic *Escherichia coli* infection     0.0105380
  T cell receptor signaling pathway           0.0167490
  Natural killer cell mediated cytotoxicity   0.0172540
  Graft-versus-host disease                   0.0174410
  Allograft rejection                         0.0186970
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